Search Results - "Baker, Jackie"

Docetaxel-related side effects and their management by Baker, Jackie, Ajani, Jaffer, Scotté, Florian, Winther, Dorte, Martin, Miguel, Aapro, Matti S, von Minckwitz, Gunter

“…Abstract Docetaxel is an effective treatment approved in five key cancers, but its effectiveness in clinical practice can be compromised by sub-optimal…”
Get full text

Optical instrument for the rapid detection of microorganisms in dairy products by Firstenberg-Eden, Ruth, Foti, Debra L, McDougal, Susan T, Baker, Jackie

“…MicroFoss, an optical instrument capable of detecting metabolic changes due to microbial activity, was tested for the detection of various groups of…”
Get full text

Shelter dogs, university employees, and lunchtime walks: A pilot study by Sartore-Baldwin, Melanie L, Baker, Jackie, Schwab, Lacey, Mahar, Matthew T, Das, Bhibha

“…Workplace walking interventions can lead to positive physical and psychological outcomes for employees. For optimal success, however, innovative approaches…”
Get more information

A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction by Blum Murphy, Mariela A, Qiao, Wei, Mewada, Nishith, Wadhwa, Roopma, Elimova, Elena, Takashi, Taketa, Ho, Linus, Phan, Alexandria, Baker, Jackie, Ajani, Jaffer

“…A randomized phase III study established docetaxel, cisplatin, and 5-fluorouracil (DCF) as one of the standard treatments for patients with untreated advanced…”
Get full text

Tesetaxel, a novel oral taxane, as second-line therapy for advanced gastroesophageal cancer: Activity in a dose-ranging study by Ajani, Jaffer A., Sun, Weijing, Rha, Sun Young, Baker, Jackie S., Mulcahy, Mary Frances

“…Abstract only 47 Background: Standard taxanes require extended IV infusion and are associated with potentially severe hypersensitivity and cumulative…”
Get full text

Phase II trial of tesetaxel, an oral taxane, as second-line therapy for patients with advanced gastroesophageal cancer by Mulcahy, Mary Frances, Baker, Jackie S., Sun, Weijing, Rha, Sun Young, Danesi, Hassan, Itri, Loretta, Ajani, Jaffer A.

“…Abstract only 4077 Background: Tesetaxel is a novel, orally administered taxane. It is not a substrate for P-glycoprotein, and preclinical data suggest…”
Get full text

Abstract A6: Association of clinical outcomes and the change in circulating soluble VEGF receptor 2 (VEGFR2) levels in advanced gastric cancer patients treated with telatinib (Tel), capecitabine (X), and cislatin (P) by Kunkel, Lori A., Fattaey, Ali, Cruikshank, Scott, Baker, Jackie, Ajani, Jaffer

“…Background: Serum VEGFA concentrations and association with metastasic disease/and or poor outcome has been well documented in gastric cancer (GC) patients…”
Get full text

Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies by Bahleda, Rastislav, Baker, Jackie, Massard, Christophe, Gadgeel, Sirish M, Rogers, Jane E, Izzedine, Hassan, Deutsch, Eric, Garris, Jeana L, Khan, Akbar, Boelle, Emmanuelle, Assadourian, Sylvie, Soria, Jean-Charles, Ajani, Jaffer A

“…This phase I study (EudraCT No. 2006-001177-25) investigated aflibercept, a vascular endothelial growth factor decoy receptor protein (VEGF Trap), in…”
Get more information

CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma results of a Phase II study by AJANI, Jaffer A, BAKER, Jackie, PISTERS, Peter W. T, HO, Linus, MANSFIELD, Paul F, FEIG, Barry W, CHARNSANGAVEJ, Chusilp

“…This Phase II study assessed the response rate and toxicity profile of the combination CPT-11 and cisplatin administered weekly to patients with untreated,…”
Get full text

An open‐label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5‐fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer : The GC4 study by Ajani, Jaffer A., Randolph Hecht, J., Ho, Linus, Baker, Jackie, Oortgiesen, Marga, Eduljee, Arnavaz, Michaeli, Dov

“…BACKGROUND Gastrin hormone is trophic to in vitro gastric cancer, and the antigastrin antibodies (AGAs) are antiproliferative and antimetastatic. Human gastric…”
Get full text

The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma by Tetzlaff, Eric D., Correa, Arlene M., Baker, Jackie, Ensor, Joe, Ajani, Jaffer A.

“…BACKGROUND. Thromboembolic events (TEEs) are considered common in patients with gastroesophageal carcinoma, but their frequency at baseline and during…”
Get full text

Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction by Fujitani, Kazumasa, Ajani, Jaffer A, Crane, Christopher H, Feig, Barry W, Pisters, Peter W, Janjan, Nora, Walsh, Garrett L, Swisher, Stephen G, Vaporciyan, Ara A, Rice, David, Welch, Angela, Baker, Jackie, Faust, Josephine, Mansfield, Paul F

“…Significant tumor downstaging has been achieved in patients with localized gastric or gastroesophageal adenocarcinoma by induction chemotherapy and…”
Get full text

Docetaxel-related side effects and their management by Baker, Jackie, Ajani, Jaffer, Scotté, Florian, Winther, Dorte, Martin, Miguel, Aapro, Matti S, von Minckwitz, Gunter

“…Docetaxel is an effective treatment approved in five key cancers, but its effectiveness in clinical practice can be compromised by sub-optimal side-effect…”
Get full text

The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma by Tetzlaff, Eric D, Correa, Arlene M, Baker, Jackie, Ensor, Joe, Ajani, Jaffer A

“…BACKGROUND. Thromboembolic events (TEEs) are considered common in patients with gastroesophageal carcinoma, but their frequency at baseline and during…”
Get full text

Impact of Induction Chemotherapy and Preoperative Chemoradiotherapy on Operative Morbidity and Mortality in Patients with Locoregional Adenocarcinoma of the Stomach or Gastroesophageal Junction by Fujitani, Kazumasa, Ajani, Jaffer A., Crane, Christopher H., Feig, Barry W., Pisters, Peter W., Janjan, Nora, Walsh, Garrett L., Swisher, Stephen G., Vaporciyan, Ara A., Rice, David, Welch, Angela, Baker, Jackie, Faust, Josephine, Mansfield, Paul F.

“…BACKGROUND: Significant tumor downstaging has been achieved in patients with localized gastric or gastroesophageal adenocarcinoma by induction chemotherapy and…”
Get full text

Corrigendum to “Docetaxel-related side effects and their management” [European Journal of Oncology Nursing 12 (2008) 253–268] by Baker, Jackie, Ajani, Jaffer, Scotté, Florian, Winther, Dorte, Martin, Miguel, Aapro, Matti S, von Minckwitz, Gunter

Get full text

REMOVED: Docetaxel-related side effects and their management by Baker, Jackie, Ajani, Jaffer, Scotté, Florian, Winther, Dorte, Martin, Miguel, Aapro, Matti S, von Minckwitz, Gunter

“…This article has been removed at the request of the Editor and Publisher. Please see Elsevier Policy on Article Withdrawal (…”
Get full text

Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma by Ajani, Jaffer A, Baker, Jackie, Pisters, Peter W, Ho, Linus, Mansfield, Paul F, Feig, Barry W, Charnsangavej, Chusilp

“…We conducted a phase II study to assess the response rate and toxicity profile of the irinotecan (CPT-11, Camptosar) plus cisplatin combination administered…”
Get more information

CPT‐11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma by Ajani, Jaffer A., Baker, Jackie, Pisters, Peter W. T., Ho, Linus, Mansfield, Paul F., Feig, Barry W., Charnsangavej, Chusilp

“…BACKGROUND This Phase II study assessed the response rate and toxicity profile of the combination CPT‐11 and cisplatin administered weekly to patients with…”
Get full text

Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma by Ajani, J A, Baker, J, Pisters, P W, Ho, L, Feig, B, Mansfield, P F

“…A phase II study was conducted to assess the response rate and toxicity profile of the combination of irinotecan (CPT-11, Camptosar) and cisplatin (Platinol)…”
Get more information